Selective costimulation modulator that inhibits T cell activation via the CD28/B7 receptor pathway. Recombinant chimeric fusion protein composed of the extracellular domain of human cytotoxic lymphocyte-associated antigen 4 (CTLA-4) fused to the heavy constant region of human IgG. Prepn: P. S. Linsley et al., J. Exp. Med. 174, 561 (1991) DOI PubMed; eidem, WO 9300431; eidem, US 5434131 (1993, 1995 both to Bristol-Myers Squibb). CE and HPLC analysis: K. F. Greve et al., J. Chromatogr. A 723, 273 (1996) DOI PubMed. Pharmacokinetics: N. R. Srinivas et al., J. Pharm. Sci. 85, 1 (1996) DOI PubMed. Clinical evaluation in psoriasis: J. R. Abrams et al., J. Clin. Invest. 103, 1243 (1999) DOI PubMed; in rheumatoid arthritis (RA): J. M. Kremer et al., Arthritis Rheum. 52, 2263 (2005) DOI PubMed; M. C. Genovese et al., N. Engl. J. Med. 353, 1114 (2005) DOI PubMed. Review of pharmacology: N. Najafian, M. H. Sayegh, Expert Opin. Invest. Drugs 9, 2147-2157 (2000) DOI PubMed; of mechanism of action and clinical development in RA: G. G. Teng et al., Expert Opin. Biol. Ther. 5, 1245-1254 (2005) DOI PubMed.
Anti-inflammatory.
Anti-inflammatory (Biological Response Modifier)